The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
mRNA expression levels of candidate genes and clinical outcome in mCRC patients treated with FOLFOXIRI plus bevacizumab (bev) or FOLFIRI plus bev in the TRIBE study.
Dongyun Yang
No relevant relationships to disclose
Fotios Loupakis
No relevant relationships to disclose
Chiara Cremolini
No relevant relationships to disclose
Carlotta Antoniotti
No relevant relationships to disclose
Marta Schirripa
No relevant relationships to disclose
Lisa Salvatore
No relevant relationships to disclose
Miriana Moran
No relevant relationships to disclose
Stephanie H. Astrow
No relevant relationships to disclose
Alfredo Falcone
No relevant relationships to disclose
Heinz-Josef Lenz
No relevant relationships to disclose